The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global artificial heart-lung machine market size reached US$ 270.6 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 339.5 Million by 2027, exhibiting a growth rate (CAGR) of 3.77% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
An artificial heart-lung machine, also known as a cardiopulmonary bypass (CPB) or oxygenator pump, is used during coronary artery bypass, heart and lung transplants, and other cardiac surgeries. It temporarily performs the functions of the heart and lungs to enable the surgeon to operate in motion and bloodless surgical field. These machines consist of a chamber that receives blood, which is then oxygenated and circulated to all body parts. Over the years, these pumps have helped in making significant advances in the management of severe respiratory failure as well as in the field of car-diac surgeries.
In recent years, there has been a significant rise in the number of open-heart surgeries, heart transplants and lung surgeries across the globe. This can primarily be attributed to various environmental and lifestyle changes, which have led to an increase in the prevalence of cardiovascular diseases and the instances of organ failures. Other than this, governments of several developing nations are making efforts for providing improved healthcare facilities to patients, which is driving the demand for artificial heart-lung machines. Furthermore, the market players are investing in research and development activities to modernize the current models of oxygenator pumps. These activities have led to the development of modular heart-lung machines that are cost-effective, safe, and user-friendly in nature. Besides this, these machines also offer flexibility to doctors as they are portable and can be operated on rechargeable batteries. The manufacturers have also made several improvements in CPB pumps to prevent the over-oxygenation of blood.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial heart-lung machine market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on type, application and end user.
Breakup by Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic Inc., Sorin Group, MAQUET GmbH & Co KG, Terumo Corporation, C.R. Bard Inc., Tianjin Welcome Medical Equipment Co., Ltd., Edwards Lifesciences, Jarvik Heart Inc., Braile Biomedica and SynCardia Systems, LLC, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Medtronic Inc., Sorin Group, MAQUET GmbH & Co KG, Terumo Corporation, C.R. Bard Inc., Tianjin Welcome Medical Equipment Co., Ltd., Edwards Lifesciences, Jarvik Heart Inc., Braile Biomedica and SynCardia Systems, LLC|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global artificial heart-lung machine market was valued at US$ 270.6 Million in 2021.
We expect the global artificial heart-lung machine market to exhibit a CAGR of 3.77% during 2022-2027.
The growing instances of organ failures and cardiovascular diseases, along with the rising focus towards providing advanced healthcare facilities to patients, are primarily driving the global artificial heart-lung machine market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing utilization of artificial heart-lung machine in the management of severe respiratory failure and in the field of cardiac surgeries, to treat coronary and respiratory side-effects among the coronavirus-infected patients.
Based on the type, the global artificial heart-lung machine market can be segmented into single roller pump and double roller pump. Currently, single roller pump holds the majority of the total market share.
Based on the application, the global artificial heart-lung machine market has been divided into cardiac surgeries, lung surgeries, acute respiratory failure treatment, and others. Among these, cardiac surgeries currently exhibit a clear dominance in the market.
Based on the end user, the global artificial heart-lung machine market can be categorized into hospitals and clinics, ambulatory surgical centers, and others. Currently, hospitals and clinics account for the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global artificial heart-lung machine market include Medtronic Inc., Sorin Group, MAQUET GmbH & Co KG, Terumo Corporation, C.R. Bard Inc., Tianjin Welcome Medical Equipment Co., Ltd., Edwards Lifesciences, Jarvik Heart Inc., Braile Biomedica, SynCardia Systems, LLC, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at